Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BuS Trial: Budesonide and Surfactant for BPD Prevention
NCT04862377Phase 3Not yet recruiting
- Sponsor
- Hospital Clínic de Barcelona
- Start
- Oct 2021
- Primary completion
- Apr 2024
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, open-label trial of budesonide in bronchopulmonary dysplasia (BPD) (3 arms), sponsored by Hospital Clínic de Barcelona. Primary endpoints: Lung Ultrasound Score at 7 days and Interleukin-6 at 7 days. Planned start Oct 2021; status: not yet recruiting.
02
Drugs
budesonide
03
Conditions
bronchopulmonary dysplasia (BPD)
Beyond the preview
Go deeper on NCT04862377.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04862377.